Journey Medical Corporation (DERM) vs Precision BioSciences, Inc. (DTIL)
A side-by-side comparison of Journey Medical Corporation and Precision BioSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DERM
Journey Medical Corporation
$6.65HealthcareDelayed quote: Oct 6, 2026, 10:03 AM EDT
DTIL
Precision BioSciences, Inc.
$6.30HealthcareDelayed quote: Oct 6, 2026, 10:04 AM EDT
Total return — DERM vs DTIL
growth of $100 · dividends reinvested · last 5yDERM -29.6% (-6.8%/yr)DTIL -97.9% (-53.7%/yr)DERM compounded faster over this window
Log scale — wide-divergence pair
DERM DTIL
DERM vs DTIL: by the numbers
- •DERM is the larger company ($183M vs $174M market cap).
- •Both run net losses; DERM's is the smaller (-8.95% vs -117.04% net margin).
- •DTIL grew revenue faster over the past five years (7.13% vs 6.75% CAGR).
Metrics side by side
Valuation
| Metric | DERM | DTIL |
|---|---|---|
| P/S ratio | 2.68 | 3.86 |
| P/B ratio | 5.69 | 3.84 |
| EV / EBITDA | 144.83 | N/A |
Profitability
| Metric | DERM | DTIL |
|---|---|---|
| Gross margin | 62.24% | 100.00% |
| Operating margin | -13.21% | -152.19% |
| Net margin | -8.95% | -117.04% |
| ROE | -19.01% | -116.42% |
| ROIC | -5.22% | -30.23% |
Growth (annualized)
| Metric | DERM | DTIL |
|---|---|---|
| Revenue CAGR (5Y) | 6.75% | 7.13% |
| Total return CAGR (5Y) | N/A | -54.84% |
Frequently asked
- Which has grown faster, DERM or DTIL?
- Over the past five years, DTIL grew revenue faster — DERM at a 6.75% CAGR versus DTIL at 7.13%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.